We are live on ! Find out more
XERS icon

Xeris Biopharma Holdings

103 hedge funds and large institutions have $150M invested in Xeris Biopharma Holdings in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 39 increasing their positions, 25 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

665% more call options, than puts

Call options by funds: $10.3M | Put options by funds: $1.35M

58% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 12

56% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 25

19% more capital invested

Capital invested by funds: $126M → $150M (+$23.4M)

7% more funds holding

Funds holding: 96103 (+7)

2.32% less ownership

Funds ownership: 52.37%50.05% (-2.3%)

Holders
103
Holders Change
+7
Holders Change %
+7.29%
% of All Funds
1.81%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
19
Increased
39
Reduced
25
Closed
12
Calls
$10.3M
Puts
$1.35M
Net Calls
+$8.96M
Net Calls Change
+$264K

XERS Hedge Fund Activity: Q1 2021 in Review

103 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q1 2021, worth a combined $150M — up 19% from $126M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new XERS positions and 12 closed out — a net gain of 7 holders — while 39 added to existing stakes and 25 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $35.3M. The largest seller was Sessa Capital, cutting an estimated $4.07M.

  • 103 institutional investors held Xeris Biopharma Holdings (XERS) as of Q1 2021, up from 96 in Q4 2020.
  • Funds reported $150M of Xeris Biopharma Holdings stock for Q1 2021, up 19% quarter-over-quarter.
  • 19 funds opened new Xeris Biopharma Holdings positions in Q1 2021 and 12 closed out, a net change of +7 holders.
  • The largest Xeris Biopharma Holdings buyer in Q1 2021 was Deerfield Management, an estimated $35.3M added.
  • The largest Xeris Biopharma Holdings seller in Q1 2021 was Sessa Capital, an estimated $4.07M sold.

Based on aggregated 13F filings for Q1 2021.